Current predictions of suitable patients for anti‐PD‐1/PD‐L1 treatment are mainly dependent on high PD‐L1 expression, high tumor mutation burden (TMB‐H and MSI‐H/dMMR), and immune cell infiltration,[3, 19] but an in vitro drug response prediction model remains lacking. The gene discussed is CD274; the disease is neoplasm.